JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[A rare mesenchymal tumor of the larynx . Case report and anatomo-clinical features].

Pathologica 1995 April
Laryngeal chondrosarcoma is an uncommon mesenchymal tumor and in the world literature only 220 cases have been reported. We report in this retrospective examination three cases which age ranged from 54 to 65 years; one was a man and two were women. Two of the tumors arose in the thyroid cartilage, one in the cricoid cartilage. All the cases corresponded to low-grade, well-differentiated chondrosarcomas of the hyaline type (grade I) and two of the patients were alive and free from recurrence or metastasis after 6 and 12 years. One had a recurrence 5 years later with a superior histologic grade (grade II) and died 6 months after laryngectomy from metastatic disease. The AA. discusses the importance of assessing location, size, state of the resection borders, histologic grade and recurrence for the correct evaluation of the neoplasia, for therapeutic and prognostic purposes.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app